Even though kidney diseases are a leading cause of death in the United States, approximately 90 percent of the estimated 37 million Americans affected by the disease do not know they have it.
The Centers for Disease Control and Prevention (CDC) says that even 40 percent of people with severely reduced kidney function (not on dialysis) are not aware of having chronic kidney disease or CKD.
“In 2019, treating Medicare beneficiaries with CKD cost $87.2 billion, and treating people with end-stage renal disease (ESRD) cost an additional $37.3 billion,” said the CDC.
The National Kidney Foundation says that kidney disease is “the under-recognized public health crisis”, causing more deaths than breast cancer or prostate cancer.
A study published in 2019 in The New England Journal of Medicine found that genes cause about 1 in 10 cases of chronic kidney disease among adults and that identifying the responsible genes has a direct impact on treatment for most of these patients.
“Our study shows that genetic testing can be used to personalize the diagnosis and management of kidney disease and that nephrologists should consider incorporating it into the diagnostic workup for these patients,” says Ali G. Gharavi, MD, Chief of Nephrology at NewYork-Presbyterian/Columbia University Irving Medical Center, and a co-senior author of the study.
A study published this year in Nephrology Dialysis Transplantation (NDT) agrees with the Columbia University study.
“The potential benefits of molecular genetic testing for inherited kidney disease are numerous,” said the authors.
Arguments put forth in the NDT article in favor of genetic testing for kidney diseases included:
“There are multiple genetic causes of chronic kidney disease, and treatment can vary depending on the cause,” says Dr. Gharavi. “And because kidney disease is often silent in the early stages, some patients aren’t diagnosed until their kidneys are close to failing, making it more difficult to find the underlying cause.”
The National Kidney Foundation says that chronic kidney disease (CKD) means your kidneys are damaged and losing their ability to keep you healthy by filtering your blood.
“In the early stages of the disease, most people do not have symptoms. But as kidney disease gets worse, wastes can build up in your blood and make you feel sick,” says the National Kidney Foundation.
The CDC says this excess fluid and waste from blood remains in the body and may cause other health problems such as heart disease and stroke. Other health consequences of CKD include:
The CDC says that CKD has varying levels of seriousness and usually gets worse over time though treatment has been shown to slow progression.
“If left untreated, CKD can progress to kidney failure and early cardiovascular disease. When the kidneys stop working, dialysis or a kidney transplant is needed for survival. Kidney failure treated with dialysis or kidney transplant is called end-stage renal disease (ESRD),” says the CDC.
The National Kidney Foundation says that diabetes and high blood pressure are the two main causes of kidney diseases:
o Glomerulonephritis (diseases that damage the kidney's filtering units
o Inherited diseases, such as polycystic kidney disease
o Malformations at birth that occur as a fetus develops
o Lupus and other immune diseases
o Obstructions such as kidney stones or an enlarged prostate
o Repeated urinary tract infections, can also lead to kidney infections and can cause long-term damage to the kidneys.
“People with kidney disease are at greater risk for cardiovascular disease and death at all stages of kidney disease. Kidney disease and heart disease are linked and have common risk factors, such as diabetes and hypertension. Each condition can lead to or worsen the other,” says the National Kidney Foundation.
The Columbia University study said that DNA sequencing has the potential to pinpoint the genetic culprits but has not been tested in a wide range of patients with chronic kidney diseases.
“Our study identifies chronic kidney disease as the most common adult disease, outside of cancer, for which genomic testing has been demonstrated as clinically essential,” says David B. Goldstein, PhD, Director of Columbia University’s Institute for Genomic Medicine and a co-senior author of the study.
In the study, researchers used DNA sequencing to look for genetic kidney disorders in 3,315 individuals with various types of chronic or end-stage kidney disease.
For 8.5 percent of these individuals, clinicians had not been able to identify the cause of disease.
The study found that:
“For several patients, the information we received from DNA testing changed our clinical strategy, as each one of these genetic diagnoses comes with its own set of potential complications that must be carefully considered when selecting treatments,” says Dr. Gharavi.
About half of the patients were diagnosed with a kidney disorder that also affects other organs and requires care from other specialists.
“These results suggest that genomic sequencing can optimize the development of new medicines for kidney disease through the selection of patient subgroups most likely to benefit from new therapies,” says Adam Platt, Ph.D., Head of Global Genomics Portfolio at AstraZeneca and a co-senior author of the study.